[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649325":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":55,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":30,"enrollmentInfo":70,"targetDuration":30,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":81,"whyStopped":30,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual care","ACTIVE_COMPARATOR","RASi restart will be deferred to the study participant's providers.",[13],"Drug: Usual Care",{"label":15,"type":16,"description":17,"interventionNames":18},"Early RASi restart strategy","EXPERIMENTAL","The early restart strategy is to resume RASi as soon as the serum creatinine (SCr) downtrends by ≥0.3mg\u002FdL from peak. In addition, the following criteria must be met: most recent potassium ≤5mEq\u002FL, SCr-based eGFR reported as ≥15 mL\u002Fmin\u002F1.73m2, and average systolic blood pressure≥120mmHg 12 hours prior to restart. If the study participant is discharged from the hospital before the RASi restart criteria are met, management of RASi restart would be deferred to the discretion of longitudinal outpatient healthcare team.",[19],"Drug: Early RASi restart strategy",[21,27],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","The early restart strategy is to resume RASi as soon as the serum creatinine (SCr) downtrends by ≥0.3mg\u002FdL from peak. In addition, the following criteria must be met: most recent potassium ≤5mEq\u002FL, CKD-EPI SCr-based eGFR reported as ≥15 mL\u002Fmin\u002F1.73m2, and average SBP ≥120mmHg 12 hours prior to restart. If the study participant is discharged from the hospital before the RASi restart criteria are met, management of RASi restart would be deferred to the discretion of longitudinal outpatient healthcare team.",[15],[26],"renin-angiotensin system inhibitors",{"type":22,"name":28,"description":11,"armGroupLabels":29,"otherNames":30},"Usual Care",[9],null,[32],{"name":33,"affiliation":5,"role":34},"Yuenting D Kwong, MD MAS","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":30,"email":39},"CONTACT","415-514-7371","diana.kwong@ucsf.edu",[41],{"facility":5,"status":30,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"San Francisco","California","94143","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-122.41942,37.77493,{"lat":51,"lon":50},[54],{"name":33,"role":37,"phone":38,"phoneExt":30,"email":39},{"type":56,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[58],{"name":59,"class":60},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100649325","phase-4-a-prompt-restart-study-of-renin-angiotensin-system-inhibitors-after-acute-kidney-injury-100649325",false,"NCT07734636","A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury","APRES-AKI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Pre-admission RASi use for Class I indication (e.g., heart failure, kidney disease)\n* RASi stopped in the setting of AKI (defined by ≥1.5x baseline SCr)\n* AKI in recovery (defined by a decrease in SCr by ≥0.3mg\u002FdL from peak)\n\nExclusion Criteria:\n\n* RASi allergy or contraindication (i.e., angioedema, bilateral renal artery stenosis)\n* Ongoing dialysis requirement\n* Pregnant or breastfeeding\n* Prisoner\n* Palliative or hospice care involvement\n* Unable to consent\n* No enteral route of medication administration\n* Clinician judgment","ALL","18 Years",{"count":71,"type":72},60,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care.\n\nStudy participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.",[78],"Acute Kidney Injury",[80],"Acute kidney injury","NOT_YET_RECRUITING","2026-07-23",{"date":84,"type":85},"2026-07-29","ACTUAL",{"date":87,"type":72},"2026-08",{"date":89,"type":72},"2029-03",{"name":5,"class":6},1]